DOCSLIB.ORG

VHD K C+V the Well-Targeted Protection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
VHD K C+V the Well-Targeted Protection VHD K C+V the well-targeted protection RHDV : Watch out for a second Strain ... Be safe : vaccinate against both RHDV1 and RHDV2 20, la Corbière - ROUSSAY - FR-49450 SEVREMOINE the prophylaxis Phone. +33 2 41 75 46 16 - Fax. +33 2 41 75 75 80 www.filavie.com The Rabbit Viral Haemorrhagic Disease New strains since 2010 WHAT ABOUT? NEW CIRCULATING VIRUSES Known in France since 1988 in its classic form, the rabbit haemorrha- Since 2010, cases of Viral Haemorrhagic Disease (VHD) on rabbits gic disease has evolved since 2010 under a variant form. This usually from properly vaccinated flocks led to the discovery of a new cali- acute disease is characterized by high mortality (up to 90% in the ab- civirus referred RHDV2 (Rabbit Haemorrhagic Disease Virus). It cur- sence of vaccination). rently represents over 90% of the cases listed in livestock and in wildlife. Specifications This virus is highly resistant in the environment: ◗ three months in carcasses, the environment and CLASSIC FORM VARIANT FORM buildings at room temperature, ◗ one month in the faeces. Agent RHDV RHDV2 Sensitivity 8-10 weeks of age From 10 days RHDV Evolution Superacute/acute Acute/chronic 100 Mortality high (70-90%) Moderate 95 87 RHDVa Lesions Icterus +/- Stronger icterus 100 UK ASHINGTON / 1998 93 FRANCE 06-11/2006 ITALY RCV / 1995 USAMRCV / 2001 Source : FRENCHRHDV VARIANT Le Gall-Reculé et al, 2011 99 RCV - A1 Ways of transmission The contamination can be made by several ways: directly orally or intra-oculary, indirectly by contaminated equipment, URINE ICTERUS EPISTAXIS feeds, vector insects, rodents Ph : Samuel Boucher There is no treatment. Prevention is based on biosecuri- ty and vaccination of sensitive populations. THE ABSENCE OF CROSSED PROTECTION IS EXPERIMENTALLY CONFIRMED This test was to compare the protection obtained by testing rabbits immunized with the classical vaccine strain alone, the variant strain alone or unvaccinated rabbits (control). Classical strain challenge (RHDV) Variant strain challenge (RHDV2) CONCLUSION no cross protection Mortality Mortality Control Vaccinated Vaccinated Control Vaccinated Vaccinated subjects CLASSIC VARIANT subjects CLASSIC VARIANT (RHDV) (RHDV2) (RHDV) (RHDV2) VHD K C+V The unique efficient bivalent vaccine against RHDV and RHDV2 strains COMPOSITION Two inactivated antigens from newly isolated virus strains: ◗ Inactivated RHDV2 (Variant strain, France, 2012), ◗ Inactivated RHDV (Classical strain, France, 2011) EFFICACY The trial was conducted in protected animal facilities. The animals were vaccinated with the FILAVAC VHD K C + V vaccine at the age of 10 weeks divided into several groups tested at 7 days, 6 and 12 months post vaccination, compared to non-vaccinated control rabbits. The challenges were performed either with the classical or the variant strain. Vaccination at 10 weeks CHALLENGES + 7 days + 6 months + 12 months Variant strain challenge (RHDV2) SAFETY Deux◗ Aluminiumvalences inactivées hydroxyde issues adjuvant de souches virales récemment isolées : ◗ Souche◗ Overdose inactivée and repeatedRHDV2 (Souche dose trial Variante, with FILAVAC France, VHD 2012), K C+V ◗ Souchevaccine inactivé on 4 weeksRHDV of(Souche age young classique, rabbits. France, 2011). › A slight rise in average temperature (+0.6°C to +0.7°C). Mortality › few local and limited reactions (granuloma on palpation) have been observed after vaccination. Classical strain challenge (RHDV) SIMPLICITY PACKAGING Mortality Single dose packaging ready-to-use Shelf-life of the veterinary medicinal product as packaged for sale : 14 months Vaccinated group Non vaccinated control CONCLUSION Installation of the immunity from 7 days and until 12 months in experimental ADMINISTRATION: Sub-cutaneous injection. conditions. The unique efficient bivalent vaccine VHD K C+V against RHDV and RHDV2 strains A vaccination protocol A packaging in accordance with the epidemiology adapted to your activity VACCINATION PROGRAM single dose packaging (Ready to be used vial) Vaccination at 10 weeks 10 weeks + 12 months Vaccination Vaccination Packaging for VHD K C+V VHD K C+V livestock (50 doses and 200 doses) 1Evaluation de l’efficacité d’un nouveau vaccin contre le virus variant de la maladie hémorragique virale du lapin (VHD) - O. LE MINOR, F. BEILVERT, T. LE MOULLEC, D.DJADOUR, J. MARTINEAU - 15ème journées de la Recherche Cunicole - Nov 2013 the prophylaxis THE EXPERT IN BIOLOGICAL IMMUNOLOGY In less than 10 years, Filavie has implemented all the means meeting the international standards GMP (Good Manufacturing Practices) and GLP (Good Laboratory Practices) allowing it to develop and register new vaccines. Filavie leaders have ma- naged to find the best specialists for the control of various steps of vaccine production: isolation, multiplication, inactivation, filling and packaging. Established in a new laboratory opened on June1st 2012, The persons in charge of the diagnosis, the production and the controls benefit from premises answering the European and Ameriican standards for the manufacturing of veterinary vaccines. A strict respect for the procedures allows to reach the quality level of the international standards. All bibliographic , scientific and regulatory references can be supplied on request made to Filavie at the following adress: [email protected]. FILAVAC VHD K C+V : 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE FILAVIE – 20, LA CORBIÈRE – 49450 ROUSSAY – FRANCE. 2. NAME OF THE VETERINARY MEDICINAL PRODUCT FILAVAC VHD K C+V suspension for injection for rabbits (1-dose). FILAVAC VHD K C+V concentrate and solvent for suspension for injection for rabbits (50-dose and 200-dose presentations). 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) 0.5 ml dose of vaccine for single-dose presentation or 0.2 ml for the 50-dose and 200- dose presentations contains: Rabbit Haemorrhagic Disease Virus strain LP.SV.2012 (variant strain 2010, RHDV2), Inactivated…min 1 PD90% * Rabbit Haemorrhagic Disease Virus strain IM507.SC.2011 (classical strain RHDV1), Inactivated…min 1 PD90% * (*)Protective dose at least 90% of the vaccinated animals. Adjuvant: Aluminium hy- droxide (Al3+): …0.35 mg. Suspension for injection (1-dose). Concentrate and solvent for suspension for injection (50-dose and 200-dose presentations). Reddish homogeneous suspension before and af- ter dilution. 4. INDICATIONS For active immunisation of rabbits (fattening and future breeders) from 10 weeks of age, to reduce mortality due to rabbit haemorrhagic disease caused by classical (RHDV1) and type 2 (RHDV2) virus strains. Onset of immunity: 7 days. Duration of immunity: 12 months. 5. CONTRAINDICATIONS None. 6. ADVERSE REACTIONS Very common: a temporary increase in body tem- perature of up to 1.6°C can be observed one day after vaccination. Common: Immunization is followed by a limited local reaction (subcutaneous nodule up to 3 mm in diameter) which may be palpable and ob- servable for at least 52 days. The frequency of adverse reactions is defined using the following convention: -very common (more than 1 in 10 animals occurring adverse reactions during the course of one treat- ment); -common (more than 1 but less than 10 animals in 100 animals); -uncommon (more than 1 but less than 10 animals in 1,000 animals); -rare (more than 1 but less than 10 animals in 10,000 animals); -very rare (less than 1 animal in 10,000 animals, including isolated reports). 7. TARGET SPECIES Rabbits. 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION Subcu- taneous use. One dose per subcutaneous injection to each animal with a volume of 0.5 ml for the single-dose presentation or 0.2 ml for the 50-dose and 200-dose presentations. First vaccination from the 10th week of age. Re-vaccination: annual. 9. ADVICE ON CORRECT ADMINISTRATION Shake well before use. Reddish homogeneous suspension (1-dose). Reddish homogeneous suspension be- fore and after dilution (50-dose and 200-dose). Apply usual aseptic conditions. Take the diluent in a sterile syringe with a sterile needle and inject the diluent into the vial of vaccine. 10. WITHDRAWAL PERIOD Zero days. 11. SPECIAL STORAGE PRECAUTIONS Keep out of the sight and reach of children. Store and transport refrigerated (2°C - 8°C). Protect from light. Do not freeze. Do not use this veterinary medicinal product after the expiry date which is stated on the label. Shelf-life of the veterinary medicinal product as packaged for sale: 14 months. Shelf-life after dilution according to directions (only for multi-dose presentation): 2 hours. 12. SPECIAL WARNING(S) Special warnings for each target species: No information is available on the use of the vaccine in seropositive animals, including animals with maternally derived antibodies. Thus, in situations where a high level of antibodies is expected, the vaccination scheme must be adjusted accordingly. The efficacy of the vaccine in animals younger than 10 weeks of age has not been demonstrated. No information is available on the safety and efficacy in pet rabbits. Special precautions for use in animals: Vaccinate only healthy rabbits. Special precautions to be taken by the person administering the veterinary medicinal product to animals: In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. This product contains aluminium hydroxide. An accidental injection to the person giving the injection may result in a local inflammatory reaction, with pain more or less severe at the point of inoculation (in particular if injection into a finger). Accidental injection to human may result in bacterial infection. As soon as possible after the accidental injection, you must: - Clean and disinfect at the point of injection. - Put ice at the zone of injection. - Seek prompt medical advice and take the package (vial, label and leaflet) insert with you. Pregnancy: The available study (field trial) has not shown abortion in pregnant animals. Use only according to the benefit-risk assessment by the responsible veterinarian. Fertility: The influence of the vaccination on the fertility of rabbits has not been investigated.
Load more

Recommended publications
  • Speech Sound Programme for 'K' / 'C' at the Start of Words
    Speech Sound Programme for ‘k’ / ‘c’ at the start of words This programme is for children who are producing a ‘t’ sound in place of a ‘k’ / ‘c’ sound at the start of words. For example, ‘cat’ is produced ‘tat’ and ‘cup’ is produced ‘tup’. ‘k’ is the target sound. ‘t’ is the produced sound. Below are a set of stages to work through with the child. Start with Stage 1 and only move up to the next stage when you are confident that the child has achieved the current stage. It is recommended that the programme is carried out for 15 minutes three times a week. If you would like any advice or you feel that the child is not making progress, please contact the Speech and Language Therapy team on 0151 514 2334. Stage 1 - Listening for the target sound 1. See ‘Picture Set 1’ for sound cue pictures that represent the target sound ‘k’ and the produced sound ‘t’. 2. Place the two pictures (‘k’ and ‘t’) in front of the child. 3. Teach the child the sounds, not the letter names, e.g., say ‘k’ and not ‘k-uh’. 4. Say the two sounds at random and ask the child to point or place a counter on which sound they hear. 5. Repeat this activity a number of times until you are sure the child can consistently hear the difference between the two sounds. Stage 2 - Sorting pictures by their first sound. 1. Now that the child can hear the difference between the two sounds (‘k’ and ‘t’) on their own, try the same with words.
    [Show full text]
  • Changes in the Risk of Stroke in Dialysis Patients: a Retrospective Analysis Over the Last 40 Years
    toxins Article Changes in the Risk of Stroke in Dialysis Patients: A Retrospective Analysis over the Last 40 Years Toshiya Aono 1,†, Yuki Shinya 1,2,*,† , Satoru Miyawaki 2 , Takehiro Sugiyama 3,4, Isao Kumagai 5, Atsumi Takenobu 1, Masahiro Shin 2 , Nobuhito Saito 2 and Akira Teraoka 1 1 Department of Neurosurgery, Teraoka Memorial Hospital, Hiroshima 729-3103, Japan; [email protected] (T.A.); [email protected] (A.T.); [email protected] (A.T.) 2 Department of Neurosurgery, The University of Tokyo Hospital, Tokyo 113-8655, Japan; [email protected] (S.M.); [email protected] (M.S.); [email protected] (N.S.) 3 Diabetes and Metabolism Information Center, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan; [email protected] 4 Department of Health Services Research, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan 5 Department of Nephrology, Teraoka Memorial Hospital, Hiroshima 729-3103, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-3-5800-8853 † These two authors have contributed equally to this study and are thus co-first authors. Abstract: The stroke incidence in hemodialysis (HD) patients is high, but the associated factors remain largely unknown. This study aimed to analyze stroke incidence in HD patients and changes in risk factors. Data of 291 patients were retrospectively analyzed. The cumulative stroke incidences were 21.6% at 10 years and 31.5% at 20. Diabetic nephropathy (DN) significantly increased overall stroke (hazard ratio (HR), 2.24; 95% confidence interval (CI), 1.21–4.12; p = 0.001) and ischemic p stroke (HR, 2.16; 95% CI, 1.00–4.64; = 0.049).
    [Show full text]
  • Chemical Kinetics [A][B] [D] [C] [A][B] [B] [A] K R Dt D Dt D K R Dt D Dt D
    Chemical kinetics (Nazaroff & Alvarez-Cohen, Section 3.A.2) This is the answer to what happens when chemical equilibrium is not reached. For example, take the two-way reaction A + B ↔ C + D As A and B come into contact with each other, they start to react with each other, and the reaction rate can be expressed as Rforward = kf [A] [B]. This expression reflects the fact that the more of A and B there is, the more encounters occur, and the more reactions take place. This rate depletes the amounts of both A and B, and generates amounts of C and D: d[A] d[B] R k [A][B] dt dt forward f d[C] d[D] R k [A][B] dt dt forward f But, at the same time, C and D come in contact, too, and carry their own, reverse reaction, at a rate proportional to their amounts Rreverse = kr [C] [D] . This rate depletes the amounts of both C and D, and adds to the amounts of A and B: d[A] d[B] R k [C][D] dt dt reverse r d[C] d[D] R k [C][D] dt dt reverse r Because the two reactions occur simultaneously, we subtract the rate of one from the other: d[A] d[B] R R k [A][B] k [C][D] dt dt forward reverse f r d[C] d[D] R R k [A][B] k [C][D] dt dt forward reverse f r 1 Finally, in a system with open boundaries, we can add the imports and exports: d[A] V Qin [A]in Qout [A]out krV[C][D] kfV[A][B] dt inlets outlets d[B] V Qin [B]in Qout [B]out krV[C][D] kfV[A][B] dt inlets outlets d[C] V Qin [C]in Qout [C]out kfV[A][B] krV[C][D] dt inlets outlets d[D] V Qin [D]in Qout [D]out kfV[A][B] krV[C][D] dt inlets outlets imports exports sources sinks where V is the volume of the system for which the budget is written.
    [Show full text]
  • Afdnk Kz K‚ Jkkkkk Kj J J J J Afdn K Kz K‚J Kk Kkk Kk Kn Kk K K Jj Am
    A Little Pretty Bonny Lass John Farmer f n ‚ J k j Cantus a D k kz k k k k k k j j j j A lit-tle pret-ty bon-ny lass was walk- ing in midst of f n J n Altus a D k kz k‚ k k k k k k k k k k k k j j A lit-tle pret-ty bon-ny lass was walk- ing, was walk-ing in midst of ‚ k k j j Tenor a f D n k kz k J k k k j k j j M A lit-tle pret-ty bon-ny lass was walk - ing in midst of k kz k k Bassus b f D n ‡ J k k k k k k j jz j j A lit-tle pret-ty bon-ny lass was walk- ing in midst of 6 1. 2. a f jz k kz k‚ k k i n k kz k‚J kz k‚ k k i May be- fore the sun 'gan rise. A lit-tle -fore the sun 'gan rise. f 1. J 2. a djz ek k k k k k k j k k k kz k‚ k k k k k k j k May be- fore the sun 'gan rise. A lit-tle -fore the sun 'gan 1. 2. f z k kz k k k z ‚ J k kz k k k a j k k ‡ k j k k k k k ‡ k j M May be- fore the sun 'gan rise.
    [Show full text]
  • K .B. NO. 'K a BILL for AN
    .B. NO. ‘k K A BILL FOR AN ACT RELATING TO THE COMPACT FOR EDUCATION. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAI’I: 1 SECTION 1. The guiding principle for the composition of 2 the membership on the Education Commission of the States from 3 each party state is that the members representing such state 4 shall, by virtue of their training, experience, knowledge, or 5 affiliations be in a position collectively to reflect broadly 6 the interests of the state government, higher education, the 7 state education system, local education, lay and professional, 8 and public and nonpublic educational leadership. In an effort 9 to follow the guiding principle and increase education expertise 10 on the Commission, the number of members appointed by the 11 Governor will increase and the Governor will be removed from the 12 Commission. The purpose of this act is to remove the Governor 13 from the Commission and replace the Governor with a fourth 14 member appointed by the Governor. 15 SECTION 2. Section 311—2(a), Hawaii Revised Statutes, is 16 amended to read as follows: 17 “311—2 State commissioners. (a) Notwithstanding section 18 A of Article III, of the Compact for Education, as enacted in GOV—02 (21) ______________________________ Page 2 .B. E\Jc. 1 section 311—1, Hawaii’s representatives to the Education 2 Commission of the States, hereinafter called the “commission”, 3 shall consist of seven members. [The govcrnor; two] Two members 4 of the legislature selected by its respective houses and serving 5 in such manner as the legislature may determine[*] and the head 6 of a state agency or institution, designated by the governor, 7 having one or more programs of public education, shall be ex 8 officio members of the commission.
    [Show full text]
  • The Alphabets of the Bible: Latin and English John Carder
    274 The Testimony, July 2004 The alphabets of the Bible: Latin and English John Carder N A PREVIOUS article we looked at the trans- • The first major change is in the third letter, formation of the Hebrew aleph-bet into the originally the Hebrew gimal and then the IGreek alphabet (Apr. 2004, p. 130). In turn Greek gamma. The Etruscan language had no the Greek was used as a basis for writing down G sound, so they changed that place in the many other languages. Always the spoken lan- alphabet to a K sound. guage came first and writing later. We complete The Greek symbol was rotated slightly our look at the alphabets of the Bible by briefly by the Romans and then rounded, like the B considering Latin, then our English alphabet in and D symbols. It became the Latin letter C which we normally read the Bible. and, incidentally, created the confusion which still exists in English. Our C can have a hard From Greek to Latin ‘k’ sound, as in ‘cold’, or a soft sound, as in The Greek alphabet spread to the Romans from ‘city’. the Greek colonies on the coast of Italy, espe- • In the sixth place, either the Etruscans or the cially Naples and district. (Naples, ‘Napoli’ in Romans revived the old Greek symbol di- Italian, is from the Greek ‘Neapolis’, meaning gamma, which had been dropped as a letter ‘new city’). There is evidence that the Etruscans but retained as a numeral. They gave it an ‘f’ were also involved in an intermediate stage.
    [Show full text]
  • Risk Factors for Incident Stroke Among Patients with End-Stage Renal Disease
    J Am Soc Nephrol 14: 2623–2631, 2003 Risk Factors for Incident Stroke among Patients with End-Stage Renal Disease STEPHEN L. SELIGER,* DANIEL L. GILLEN,† DAVID TIRSCHWELL,‡ HAIMANOT WASSE,* BRYAN R. KESTENBAUM,* and CATHERINE O. STEHMAN-BREEN§ *Division of Nephrology, University of Washington, Seattle, Washington; †Department of Biostatistics, University of Washington School of Public Health and Community Medicine, Seattle, Washington; ‡Department of Neurology, University of Washington, Seattle, Washington; and §Division of Nephrology, Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington Abstract. Although patients with ESRD experience markedly were associated with the risk of stroke—serum albumin (per higher rates of stroke, no studies in the US have identified 1 g/dl decrease, hazard ratio [HR] ϭ 1.43), height-adjusted risk factors associated with stroke in this population. It was body weight (per 25% decrease, HR ϭ 1.09), and a subjec- hypothesized that black race, malnutrition, and elevated BP tive assessment of undernourishment (HR ϭ 1.27)—as was would be associated with the risk of stroke among patients higher mean BP (per 10 mmHg, HR ϭ 1.11). The associa- with ESRD. Data from the United States Renal Data Sys- tion between black race varied by cardiac disease status, tems were used. Adult Medicare-insured hemodialysis and with blacks estimated to be at lower risk than whites among peritoneal dialysis patients without a history of stroke or individuals with cardiac disease (HR ϭ 0.74), but at higher transient ischemic attack (TIA) were considered for analy- risk among individuals without cardiac disease (HR ϭ sis.
    [Show full text]
  • 1 Mol .08314 Bar L Mol K 298 K 12.2 Bar 2.03 L Nrt V P =
    University Chemistry Quiz 6 2015/01/08 1. (5%) Explain why the value of S° for graphite is greater than that for diamond at 298K (use table2). Would this inequality hold at 0 K? A diamond is essentially a macroscopic molecule with no internal rotational or translational states. Graphite consists of large sheets of carbon that are bound to each other via intermolecular interactions. Consequently, it also has no significant internal rotational or translational states. But, since the sheets in graphite are free to slide past one another with relative ease (graphite makes a fine dry-lubricant), it does exhibit modes that are less like vibrations and more like translations, and we expect then that 1 mol of graphite will have greater entropy than diamond at a fixed temperature and pressure. In the absence of frozen-in residual entropy, the molar entropies of the two substances will both approach zero as the temperature is lowered. 2. (10%) One mole of an ideal gas at 298K expands isothermally from 1.0 to 2.0 L (a) reversibly and (b) against a constant external pressure of 12.2 bar. Calculate ΔSsys, ΔSsurr, and ΔSuniv in both cases. Are your results consistent with the nature of the process? Sol. (a) Use equation 8.10: 푉2 −1 −1 2.0 퐿 −ퟏ ∆푆푠푦푠 = 푛푅 ln = 1 푚표푙 8.314 퐽 푚표푙 퐾 ln = ퟓ. ퟕퟔ 푱 푲 푉1 1.0 퐿 Since the process is reversible, Suniv = 0 and - 1 SSsurr= - sys = - 5.76 J K . (b) Use the ideal gas equation to find the volume of the final state: nRT V2 = P2 (1 mol)( .08314 bar L mol--11 K)( 298 K) = 12.2 bar = 2.03 L Next, use equation 8.10 to find the entropy change of the system: 푉2 −1 −1 2.03 퐿 −ퟏ ∆푆푠푦푠 = 푛푅 ln = 1 푚표푙 8.314 퐽 푚표푙 퐾 ln = ퟓ.
    [Show full text]
  • Rule 46. Admission to the Bar
    Rule 46. Admission to the Bar. (a) Committee on Admissions. (1) The court shall appoint a standing committee known as the Committee on Admissions (Committee) consisting of at least seven members of the Bar of this court, one of whom shall serve as counsel to the Committee. Each appointment shall be for a term of three years. In case of a vacancy arising before the end of a member’s term, the successor appointed shall serve the unexpired term of the predecessor member. When a member holds over after the expiration of the term for which that member was appointed, the time served after the expiration of that term shall be part of a new term. No member shall be appointed to serve longer than two consecutive regular three-year terms, unless an exception is made by the court. (2) Subject to the approval of the court, the Committee may adopt such rules and regulations as it deems necessary to implement the provisions of this rule. The members of the Committee shall receive such compensation and necessary expenses as the court may approve. (3) Members of the Committee and their lawfully appointed designees and staff are immune from civil suit for any conduct in the course of their official duties. (b) Admission to the Bar of this jurisdiction. Admission may be based on (1) examination in this jurisdiction; (2) transfer of a Uniform Bar Examination score attained in another jurisdiction; (3) the applicant’s qualifying score on the Multistate Bar Examination administered in another jurisdiction and membership in the bar of such other jurisdiction; or (4) membership in good standing in the bar of another jurisdiction for at least five years immediately prior to the application for admission.
    [Show full text]
  • Roman Numerals
    ROMAN NUMERALS Romans developed a different system of numeration about 2000 years ago Roman numerals. There are seven basic Roman numerals. These numerals and corresponding Hindu Arabic numerals are given below. Roman Numerals I V X L C D M Hindu- Arabic 1 5 10 50 100 500 1000 Numerals Writing Numbers in Roman Numerals You already know about the numerals I, V and X and the method to write numbers up to 39. Here, we will learn how to write large numbers using Roman numerals. Note! There is no symbol form in Roman system Rule 1 When a letter is used more than once, we add its value each time to get the number Examples: II= 1 + 1 = 2 XXX = 10 + 10 + 10 = 30 CCC = 100 + 100 + 100 MM = 1000 + 1000 = 2000 MMM = 1000 + 1000 + 1000 = 3000 Note! 1. The some symbol cannot be repeated more than 3 times together 2. The symbol V, L ond ore never repeated Rule 2 When a symbol of smaller value is written to the right of a symbol of larger value, add the two values. Examples: VII = 5 +1+1= 7 XXVII = 10 + 10 + 5 + 1 + 1 = 27 LXVI = 50 + 10 + 5+1 = 66 CLXV = 100 + 50 + 10 + 5 = 165 XII = 10 +1+1= 12 LVII = 50 + 5 + 1 + 1 = 57 CVII = 100 + 5 +1+1 = 107 DC = 500 + 100 = 600 MDCXVIII = 1000 + 500 + 100 + 10 + 5 +1+1 +1 = 1618 Rule 3 When a symbol of smaller value is written to the left of a symbol of larger value, the smaller value is subtracted from the larger value.
    [Show full text]
  • Faliscan the Alphabet
    W. D. C. de Melo Faliscan The alphabet General remarks The various alphabets of ancient Italy go back to a Western Greek alphabet, which in turn is derived from the Phoenician alphabet. The names of the letters make sense in Phoenician, but not in Greek: the second letter has the sound value b (Greek b¯eta) and is the word for ‘house’, a word which in Phoenician began with b (Hebrew bayit, st. constr. b¯et). In (most? all?) Semitic languages words cannot begin with a vowel; since the letter names are nouns in origin and the letters just stand for the first sound of these nouns, this may explain why ancient Semitic languages do not write vowels consistently. The great innovation in the Greek alphabets is that the old signs for pharyngeal and glottal consonants, for which Greek had no use, were redeployed as vowel signs. Learning the alphabet and the consequences The alphabet had a fixed order of letters. The names of the letters were learnt by heart in this fixed order and people also had tables with the letter forms, again in the same order, so that they could associate sound and shape. When people knew the alphabet, they could begin with simple syllables (con- sonant + vowel), after which they began to write more complex syllables, and finally words. Around 600BC, the Etruscans invented a teaching aid: simple syllables with a CV shape are left as they are, but around any letter that does not fit into this syllabe pattern dots are placed on either side. The speakers of Venetic adopted this system of syllabic punctuation (though not in their earliest inscriptions), which to us may seem bizarre: voto klutiiari.s.
    [Show full text]
  • K/ & /G/ ISOLATION & SYLLABLES /K/: to Produce the /K/ Sound, Open Your
    /k/ & /g/ ISOLATION & SYLLABLES /k/: To produce the /k/ sound, open your mouth, relax your tongue, and make a coughing sound as you push the air out of your mouth. The back of your tongue will come up as this happens and make contact with the roof of the mouth in the far back. Sometimes it is difficult to get little one’s to keep their tongue down to make a good /k/ sound. It often comes out sounding like a /t/ sound. I will use a tongue depressor to keep the front of their tongue down as we practice /k/ in isolation. If we still can’t get the sound, have them lie down on their backs and open their mouth. Their tongue falls in the back of their mouth naturally, which is the place for /k/. Add vowel sounds after the sound to produce syllables. (kay, key, kie, kou, coo) These still might have to be separated to get a good /k/ sound: ie. k—ay, k—ey) /g/: To produce the /g/ sound, repeat steps for /k/, but turn your voice on. You can put your fingers (or have them put their fingers) on their “adam’s apple” spot to feel their voice turn on for /g/ and off for /k/. Sometimes it is difficult to get little one’s to keep their tongue down to make a good /g/ sound. It often comes out sounding like a /d/ sound. I will use a tongue depressor to keep the front of their tongue down as we practice /g/ in isolation.
    [Show full text]